149 related articles for article (PubMed ID: 17631562)
1. Radiotherapy for localized rectal cancer.
Deutsch E; Ezra P; Mangoni M; Ducreux M
Ann Oncol; 2007 Jul; 18 Suppl 9():ix105-13. PubMed ID: 17631562
[No Abstract] [Full Text] [Related]
2. [Principles of postoperative therapy in rectal carcinoma].
Folprecht G; Köhne CH
Chirurg; 2004 Jan; 75(1):32-7. PubMed ID: 14740125
[TBL] [Abstract][Full Text] [Related]
3. Colon cancer: new drug options improve on 5-FU.
McCann J
J Natl Cancer Inst; 1998 Jul; 90(13):963-5. PubMed ID: 9665142
[No Abstract] [Full Text] [Related]
4. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
5. Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Taguchi T
Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():76-80. PubMed ID: 11890118
[No Abstract] [Full Text] [Related]
6. Treatment of advanced disease and new drugs.
Frustaci S; Buonadonna A; La Mura N; Berretta M; De Paoli A
Suppl Tumori; 2003; 2(5):S48-50. PubMed ID: 12914391
[No Abstract] [Full Text] [Related]
7. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
Heudel P; Romestaing P; Barbet N; Falandry C; You B; Glehen O; Freyer G
Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):369-74. PubMed ID: 18406583
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.
Zhu AX; Willett CG
Semin Radiat Oncol; 2003 Oct; 13(4):454-68. PubMed ID: 14586834
[TBL] [Abstract][Full Text] [Related]
10. The role of capecitabine in the management of tumors of the digestive system.
Gennatas C; Michalaki V; Gennatas S
Rev Recent Clin Trials; 2009 Jan; 4(1):1-11. PubMed ID: 19149758
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
12. [Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer].
Xiao L; Gao Y; Liu M
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Jan; 17(1):93-7. PubMed ID: 24519058
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
Ugidos L; Delgado S; Conill C; Ginés A; Gallego R; Ayuso JR; Miquel R; Tosca M; de Lacy A; Castells A; Maurel J
Invest New Drugs; 2009 Jun; 27(3):262-8. PubMed ID: 18923810
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
[TBL] [Abstract][Full Text] [Related]
15. [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Créhange G; Bosset JF; Maingon P
Cancer Radiother; 2011 Oct; 15(6-7):440-4. PubMed ID: 21802334
[TBL] [Abstract][Full Text] [Related]
16. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Pfeiffer P; Sørbye H; Ehrsson H; Fokstuen T; Mortensen JP; Baltesgard L; Tveit KM; Øgreid D; Starkhammar H; Wallin I; Qvortrup C; Glimelius B
Ann Oncol; 2006 Feb; 17(2):252-8. PubMed ID: 16291583
[TBL] [Abstract][Full Text] [Related]
17. [A review of chemotherapy for metastatic colon cancer].
Díez-Fernández R; Salinas Hernández P; Girón-Duch C
Farm Hosp; 2006; 30(6):359-69. PubMed ID: 17298193
[TBL] [Abstract][Full Text] [Related]
18. What's new in ... colorectal cancer. Meaningful progress in therapy options.
Polansky M; Ross AC
JAAPA; 2009 Apr; 22(4):51-2. PubMed ID: 19452823
[No Abstract] [Full Text] [Related]
19. An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Haghighat P; Bekaii-Saab T
J Natl Compr Canc Netw; 2008 Oct; 6(9):895-900. PubMed ID: 18926099
[TBL] [Abstract][Full Text] [Related]
20. The role of new agents in the treatment of colorectal cancer.
Folprecht G; Köhne CH
Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
